The application of in silico experimental model in the assessment of ciprofloxacin and levofloxacin interaction with main SARS-CoV-2 targets: S-, E- and TMPRSS2 proteins, RNA-dependent RNA polymerase and papain-like protease (PLpro)—preliminary molecular docking analysis
Background The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified at the end of 2019. Despite growing understanding of SARS-CoV-2 in virology as well as many molecular studies, except remdesivir, no specific anti-SARS-CoV-2 drug has been officially approved. Methods In the present study molecular docking technique was applied to test binding affinity of ciprofloxacin and levofloxacin—two commercially available fluoroquinolones, to SARS-CoV-2 S-, E- and TMPRSS2 proteins, RNA-dependent RNA polymerase and papain-like protease ($ PL^{PRO} $). Chloroquine and dexamethasone were used as reference positive controls. Results When analyzing the molecular docking data it was noticed that ciprofloxacin and levofloxacin possess lower binding energy with S protein as compared to the references. In the case of TMPRSS2 protein and $ PL^{PRO} $ protease the best docked ligand was levofloxacin and in the case of E proteins and RNA-dependent RNA polymerase the best docked ligands were levofloxacin and dexamethasone. Moreover, a molecular dynamics study also reveals that ciprofloxacin and levofloxacin form a stable complex with E- and TMPRSS2 proteins, RNA polymerase and papain-like protease ($ PL^{PRO} $). Conclusions The revealed data indicate that ciprofloxacin and levofloxacin could interact and potentially inhibit crucial SARS-CoV-2 proteins..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
---|---|
Enthalten in: |
Pharmacological reports - 73(2021), 6 vom: 30. Mai, Seite 1765-1780 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Marciniec, Krzysztof [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
) |
Anmerkungen: |
© The Author(s) 2021 |
---|
doi: |
10.1007/s43440-021-00282-8 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2077469005 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC2077469005 | ||
003 | DE-627 | ||
005 | 20230514105517.0 | ||
007 | tu | ||
008 | 221220s2021 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s43440-021-00282-8 |2 doi | |
035 | |a (DE-627)OLC2077469005 | ||
035 | |a (DE-He213)s43440-021-00282-8-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
084 | |a PHARM |q DE-84 |2 fid | ||
084 | |a 15,3 |2 ssgn | ||
084 | |a 44.40$jPharmazie$jPharmazeutika |2 bkl | ||
100 | 1 | |a Marciniec, Krzysztof |e verfasserin |4 aut | |
245 | 1 | 0 | |a The application of in silico experimental model in the assessment of ciprofloxacin and levofloxacin interaction with main SARS-CoV-2 targets: S-, E- and TMPRSS2 proteins, RNA-dependent RNA polymerase and papain-like protease (PLpro)—preliminary molecular docking analysis |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © The Author(s) 2021 | ||
520 | |a Background The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified at the end of 2019. Despite growing understanding of SARS-CoV-2 in virology as well as many molecular studies, except remdesivir, no specific anti-SARS-CoV-2 drug has been officially approved. Methods In the present study molecular docking technique was applied to test binding affinity of ciprofloxacin and levofloxacin—two commercially available fluoroquinolones, to SARS-CoV-2 S-, E- and TMPRSS2 proteins, RNA-dependent RNA polymerase and papain-like protease ($ PL^{PRO} $). Chloroquine and dexamethasone were used as reference positive controls. Results When analyzing the molecular docking data it was noticed that ciprofloxacin and levofloxacin possess lower binding energy with S protein as compared to the references. In the case of TMPRSS2 protein and $ PL^{PRO} $ protease the best docked ligand was levofloxacin and in the case of E proteins and RNA-dependent RNA polymerase the best docked ligands were levofloxacin and dexamethasone. Moreover, a molecular dynamics study also reveals that ciprofloxacin and levofloxacin form a stable complex with E- and TMPRSS2 proteins, RNA polymerase and papain-like protease ($ PL^{PRO} $). Conclusions The revealed data indicate that ciprofloxacin and levofloxacin could interact and potentially inhibit crucial SARS-CoV-2 proteins. | ||
650 | 4 | |a Fluoroquinolones | |
650 | 4 | |a E protein | |
650 | 4 | |a S protein | |
650 | 4 | |a TMPRSS2 protein | |
650 | 4 | |a RNA-dependent RNA polymerase | |
650 | 4 | |a Papain-like protease (PL | |
650 | 4 | |a ) | |
700 | 1 | |a Beberok, Artur |0 (orcid)0000-0003-2247-3004 |4 aut | |
700 | 1 | |a Boryczka, Stanisław |4 aut | |
700 | 1 | |a Wrześniok, Dorota |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pharmacological reports |d Springer International Publishing, 2005 |g 73(2021), 6 vom: 30. Mai, Seite 1765-1780 |w (DE-627)485244918 |w (DE-600)2186248-5 |w (DE-576)435514369 |x 1734-1140 |7 nnns |
773 | 1 | 8 | |g volume:73 |g year:2021 |g number:6 |g day:30 |g month:05 |g pages:1765-1780 |
856 | 4 | 1 | |u https://doi.org/10.1007/s43440-021-00282-8 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a FID-PHARM | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
912 | |a SSG-OPC-PHA | ||
936 | b | k | |a 44.40$jPharmazie$jPharmazeutika |q VZ |0 106423304 |0 (DE-625)106423304 |
951 | |a AR | ||
952 | |d 73 |j 2021 |e 6 |b 30 |c 05 |h 1765-1780 |